Compare Gilead Sciences, Inc. (GILD) vs Kohl's Corporation (KSS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Kohl's Corporation — how do they compare? Gilead Sciences, Inc. trades at $148.65 (market cap $182.40B), while Kohl's Corporation trades at $20.19 (market cap $2.28B). The key difference: Gilead Sciences, Inc. is far larger — about 80× Kohl's Corporation's market cap, and Kohl's Corporation pays the higher dividend (2.49%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Kohl's Corporation for 48 Days on average.
| GILD | KSS | |
|---|---|---|
Market Cap | $182.40B | $2.28B |
Volume | 4,469,821 | 4,960,280 |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $24.71 |
52-Week Low | $116.74 | $11.72 |
Typical Hold Time | 111 Days | 48 Days |
Enterprise Value | $205.46B | $7.88B |
Dividend Yield | 2.23% | 2.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
Kohl's (KSS) trades at $20.12, up 2.5% today, with a bullish technical signal driven by moving averages but overbought RSI readings. The stock shows deep value with a P/E of 8.63 and P/B of 0.55, though revenue has declined annually since 2022. Recent Q2 2026 earnings beat estimates with EPS of $1.28, and the company raised full-year guidance, supported by margin gains and a new chief merchandising officer appointment.
The outlook is mixed: low valuation and earnings momentum offer upside, but persistent sales declines and competitive pressures pose risks. Analyst consensus is cautious with a $15.50 price target below the current price, reflecting skepticism about the sustainability of the turnaround amid consumer spending shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Kohl's Corporation
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →
